Table Of Contents

1. Introduction
1.1. Overview Of Europe Self-Injection Market
1.2. Currency And Pricing
1.3. Limitation
1.4. Markets Covered
2. Market Segmentation
2.1. Markets Covered
2.2. Geographic Scope
2.3. Years Considered For The Study
2.4. Currency And Pricing
2.5. Research Methodology
2.6. Primary Interviews With Key Opinion Leaders
2.7. Secondary Sources
2.8. Assumptions
3. Market Overview
3.1. Drivers
3.1.1. Rising Cases Of Chronic Diseases
3.1.2. Rising Demand Of Self-Injection Devices
3.1.3. Growth Of Biologics Market
3.1.4. Technological Advancements And Innovations In Drug Delivery Market
3.2. Restraints
3.2.1. High Cost Of Development
3.2.2. Strict Regulatory Framework
3.3. Opportunity
3.3.1. Increasing Demand For Generic And Biosimilar Drugs
3.3.1.1. Generics
3.3.1.2. Biosimilars
3.3.2. Increasing Demand For Contraceptive Injectables
3.3.3. Increasing Demand For Self-Administration Of Drugs
3.4. Challenges
3.4.1. Alternative Route Of Drug Administration
3.4.2. Product Recall
3.4.3. Stability Of Products
3.4.4. Sterility Of Injections
4. Executive Summary
5. Premium Insights
6. Europe Self-Injection Market, Regulatory
6.1. Overview
6.2. U.S. Fda Approval
6.3. Ce Marking (European Conformity)
7. Europe Self-Injection Market, Reimbusement
7.1. Overview
7.2. Reimbursement Scenario
8. Europe Self-Injection Market, By Type
8.1. Overview
8.2. Europe Self-Injection Market, By Product Type
8.2.1. Needle Free Injectors (Nfi)
8.2.1.1. Needle Free Injectors, By Product
8.2.1.2. Needle Free Injectors, By Technology
Laser Based Needle Free Injectors;
Vibration Based Needle Free Injectors;
8.2.1.3. Needle Free Injectors, By Usability
Reusable Needle-Free Injectors
Disposable Needle-Free Injectors
8.2.2. Auto Injectors
8.2.2.1. Auto Injectors, By Product
Fillable Auto Injectors
Pre-Filled Auto Injectors
8.2.2.2. Auto Injectors, By Technology
Automated Auto Injectors
Manual Auto Injectors
8.2.2.3. Auto Injectors, By Design
Standardized Auto Injectors
Customizedauto Injectors
8.2.2.4. Auto Injectors, By Usability
Reusable Auto Injectors
Disposable Auto Injectors
8.2.3. Pen Injectors
8.2.3.1. Pen Injectors, By Product
Single Chambered Pen Injectors
Dual Chambered Pen Injectors
8.2.3.2. Pen Injectors, By Design
Standard Pen Injectors
Customized Pen Injectors
8.2.3.3. Pen Injectors, By Usability
Reusable Pen Injectors
Disposable Pen Injectors
8.2.4. Wearable Injectors
9. Europe Self-Injection Market, By Application
9.1. Overview
9.2. Europe Self-Injection Market, By Application
9.3. Hormonal Disorders
9.3.1. Self-Injections For Diabetes
9.3.2. Self-Injectionsfor Anemia
9.3.3. Reproductive Health Disease
9.3.4. Osteoporosis
9.3.5. Growth Hormone Disorders (Ghd)
9.4. Oncology
9.5. Autoimmune Diseases
9.5.1. Rheumatoid Arthritis
9.5.2. Multiple Sclerosis
9.5.3. Crohn?S Diseases
9.5.4. Psoriasis
9.5.5. Other Autoimmune Diseases
9.6. Orphan Disease
9.7. Other Applications
9.7.1. Pain Management
9.7.2. Allergy Treatment
9.7.3. Aesthetic Treatments
9.7.4. Hepatitis C
9.7.5. Hemophilia
10. Europe Self-Injection Market, By Usage Pattern
10.1. Overview
10.2. Curative Care
10.3. Immunizations
10.4. Other Usage Pattern
11. Europe Self-Injection Market, By Mode Of Administration
11.1. Overview
11.2. Skin
11.3. Circulatory/ Muskoskeletal
11.4. Organs
11.5. Central Nervous System
12. Europe Self-Injection Market, By End User
12.1. Overview
12.2. Hospitals And Clinics
12.3. Home Healthcare Settings
12.4. Research Laboratories
12.5. Pharmaceutical And Biotechnological Companies
12.6. Other End User
13. Europe Self-Injection Market, By Distribution Channel
13.1. Overview
13.1.1. Hospital Pharmacy
13.1.2. Pharmacy Stores
13.1.3. Direct Tender
13.1.4. Online Pharmacy
14. Europe Self-Injection Market, By Geography
14.1. Overview
14.2. Europe
14.2.1. Germany
14.2.2. France
14.2.3. Uk
14.2.4. Switzerland
14.2.5. Spain
14.2.6. Italy
14.2.7. Netherlands
14.2.8. Russia
14.2.9. Turkey
14.2.10. Belgium
14.2.11. Rest Of Europe
15. Europe Self Injection Market, Company Landscape
15.1. Company Share Analysis; Europe
15.2. Company Share Analysis; North America
15.3. Company Share Analysis; Europe
15.4. Company Share Analysis; Asia-Pacific
16. Company Profiles
16.1. Elcam Medicalcompany Overview
16.1.1. Elcam Medical; Company Snapshot
16.1.2. Product Portfolio
16.1.3. Recent Developments
16.2. Bespak (Subsidiary Of Consort Medical Company)
16.2.1. Company Overview
16.2.2. Bespak; Revenue Analysis
16.2.3. Product Portfolio
16.2.4. Recent Developments
16.3. Sanofi
16.3.1. Company Overview
16.3.2. Sanofi ; Revenue Analysi
16.3.3. Product Portfolio
16.3.4. Recent Developments
16.4. Sandoz International Gmbh
16.4.1. Company Overview
16.5. Sandoz International Gmbh; Revenue Analysis
16.5.1. Product Portfolio
16.5.2. Recent Developments
16.6. Unilife Corporation
16.6.1. Company Overview
16.6.2. Unilife Corporation; Revenueanalysis
16.6.3. Product Portfolio
16.6.4. Recent Developments
16.7. West Pharmaceutical Services, Inc
16.7.1. Company Overview
16.7.2. West Pharmaceutical Services, Inc; Revenue Analysis
16.7.3. Product Portfolio
16.7.4. Recent Developments
16.8. Pfizer Inc.
16.8.1. Company Overview
16.8.2. Pfizer Inc; Revenue Analysis
16.8.3. Product Portfolio
16.8.4. Recent Developments
16.9. Impax Laboratories, Inc.
16.9.1. Company Overview
16.9.2. Impax Laboratories, Inc; Revenue Analysis
16.9.3. Product Portfolio
16.9.4. Recent Developments
16.10. Penjet Corporation
16.10.1. Company Overview
16.10.2. Penjet Corporation; Company Snapshot
16.10.3. Product Portfolio
16.10.4. Recent Developments
16.11. Crossject Needle-Free Injection Systems
16.11.1. Company Overview
16.11.2. Crossject Needle-Free Injection Systems; Company Snapshot
16.11.3. Product Portfolio
16.11.4. Recent Developments
16.12. Wilhelm Haselmeier Gmbh & Co. Kg
16.12.1. Company Overview
16.12.2. Haselmeier; Company Snapshot
16.12.3. Product Portfolio
16.12.4. Recent Developments
?
16.13. Antares Pharma
16.13.1. Company Overview
16.13.2. Antares Pharma; Revenue Analysis
16.13.3. Product Portfolio
16.13.4. Recent Developments
16.14. Becton, Dickinson And Company
16.14.1. Company Overview
16.14.2. Becton, Dickinson And Company; Revenue Analysis
16.14.3. Product Portfolio
16.14.4. Recent Developments
16.15. Gerresheimer Ag
16.15.1. Company Overview
16.15.2. Gerresheimer Ag; Revenue Analysis
16.15.3. Product Portfolio
16.15.4. Recent Developments
16.16. Mylan N.V
16.16.1. Company Overview
16.16.2. Mylan N.V.; Revenue Analysis
16.16.3. Product Portfolio
16.16.4. Recent Developments
16.17. Novo Nordisk
16.17.1. Company Overview
16.17.2. Novo Nordisk; Revenue Analysis
16.17.3. Product Portfolio
16.17.4. Recent Developments
16.18. Owen Mumford Ltd
16.18.1. Company Overview
16.18.2. Owen Mumford Ltd; Company Snapshot
16.18.3. Product Portfolio
16.18.4. Recent Developments
16.19. Pharmajet
16.19.1. Company Overview
16.19.2. Pharmajet; Company Snapshot
16.19.3. Product Portfolio
16.19.4. Recent Developments
16.20. Shl Group
16.20.1. Company Overview
16.20.2. Shl Group; Company Snapshot
16.20.3. Product Portfolio
16.20.4. Recent Developments
16.21. Ypsomed
16.21.1. Company Overview
16.21.2. Ypsomed; Revenue Analysis
16.21.3. Product Portfolio
16.21.4. Recent Developments
17. Related Reports